GlassScriptPhysician profile
Lloyd A Bonner
NPI 1821086646
$4,262.33
in general payments reported to CMS, 2019-2025
48 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $147 · 2021: $972 · 2022: $887 · 2023: $914 · 2024: $421 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,472 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,472.40 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $692.82 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $291.13 | 2019-2023 | |
| Abbott Laboratories | $284.67 | 2020-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $256.50 | 2021-2023 | |
| Abbvie INC. | $231.93 | 2021-2023 | Vraylar, Ubrelvy |
| Sanofi-Aventis U.S. LLC | $205.93 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $177.46 | 2019-2023 | |
| Lilly USA, LLC | $166.88 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $166.00 | 2021-2025 | Repatha, Repatha, Otezla |
| Astellas Pharma US INC | $142.36 | 2019-2021 | |
| Amarin Pharma, INC. | $103.49 | 2019 | |
| Corium, LLC | $100.25 | 2022-2023 | Adlarity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.79 | 2021 | |
| Sunovion Pharmaceuticals INC. | $84.21 | 2019-2022 | |
| Bioventus LLC | $82.79 | 2023-2024 | Durolane, Gelsyn-3 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lloyd Bonner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.